ProMIS Neurosciences is trading 6.61% lower at $8.12 amid a reported biotech-sector selloff. - XBI is down 2.06% during the regular session, consistent with weakness among smaller biotech stocks. - The company’s investor news page lists an October 6 appointment as its latest announcement, not a new October 16 catalyst. No clear company-specific explanation for the drop was found.